BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety …

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a biopharmaceutical company focused on developing medicines for genetic conditi… [+3205 chars]

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions - FHMnews